Skip to main content

The PRIORITY trial

The PRIORITY investigators recruited people with type 2 diabetes and normoalbuminuria, and categorized them as being at high or low risk for progression to diabetic nephropathy based on the previously developed proteomic panel of urinary peptides, CKD273.

Those considered at high risk were randomly assigned to receive the diuretic spironolactone or placebo, and the team will report the effects of this intervention on the primary endpoint of microalbuminuria.

PRIORITY results published: Biomarker panel can predict diabetic nephropathy progression

Luigi Gnudi discusses the findings of the PRIORITY trial and addresses whether diabetologists should consider intervening earlier in diabetic nephropathy (4:08).

Read the interview transcript

Results from the PRIORITY trial were presented at the 55th EASD Annual Meeting (EASD 2019):

Proteomic prediction and Renin angiotensin aldosterone system Inhibition prevention Of early diabetic nephRopathy In TYpe 2 diabetic patients with normoalbuminuria: (PRIORITY) study 
Thursday, September 19, 13:15–14:15. Vilanova Hall, Ochoa Hall, Fira Barcelona Gran Via, Spain 
Session Chair: C. Delles, UK

  1. Urinary proteomic prediction of albuminuria and eGFR progression. G. Currie, UK
  2. Effect of aldosterone blockade on progression to microalbuminuria in high risk subjects. M. K. Lindhardt, Denmark
  3. Conclusions. P. Rossing, Denmark

Back to the EASD 2019 conference hub